CLL
Conference Coverage
ICLL-07 trial: MRD-driven strategy yields prolonged survival
EDINBURGH - In the phase 2 ICLL-07 trial, induction with obinutuzumab and ibrutinib followed by an MRD-driven treatment strategy for CLL yielded a...
Conference Coverage
GALACTIC CLL trial: Obinutuzumab consolidation helps eradicate MRD
EDINBURGH – Obinutuzumab consolidation after chemoimmunotherapy for B-CLL was highly effective for eradicating MRD within 6 months post...
From the Journals
CK doesn’t seem to affect OS in CLL patients taking idelalisib
Data from two clinical trials of idelalisib showed no significant difference in overall survival between patients with and without complex...
News
Calquence earns breakthrough designation for CLL monotherapy
The Bruton tyrosine kinase inhibitor is already approved for the treatment of adults with mantle cell lymphoma who have received at least one...
From the Journals
Zanubrutinib may be poised to challenge ibrutinib for CLL
The phase 1 study had a 96% overall response rate and there were no dose-limiting toxicities.
From the Journals
ICYMI: Ibrutinib/rituximab combo improves CLL survival
Progression-free and overall survival were superior in patients receiving ibrutinib and rituximab, compared with standard chemotherapy.
From the Journals
BTK mutations linked to CLL progression on ibrutinib
The findings support mutational analysis in CLL patients on ibrutinib, according to researchers.
News
FDA approves rituximab biosimilar for cancer, autoimmune disorders
The biosimilar is approved for certain cancers and autoimmune disorders, although, like its reference drug, it comes with a boxed warning from the...
From the Journals
Ibrutinib-venetoclax found highly active in hard-to-treat CLL
Trial results suggest the two drugs may have synergistic efficacy when used together, and raise the possibility of achieving MRD negativity with...
Opinion
Potential improvements in convenience, tolerability of hematologic treatment
Dr. Alan P. Lyss dissects the practice changing elements of the COLUMBA trial in multiple myeloma and the ASCEND trial in CLL.
Conference Coverage
Acalabrutinib extends PFS in advanced CLL
AMSTERDAM – Monotherapy with the Bruton tyrosine kinase inhibitor acalabrutinib offered better progression-free survival, compared with rituximab-...